Celerity Pharmaceuticals

Celerity Pharmaceuticals is a company that Water Street created in partnership with one of the world’s leading pharmaceutical corporations to support it with maximizing its drug development investment.  Water Street invested in Celerity in 2013 to lead development of multiple generic product families on behalf of our pharmaceutical partner.  Once the products receive regulatory approval, the corporation will purchase them from Water Street at a previously agreed-upon price.  We engaged Al Heller, a Water Street operating partner who has more than 35 years of pharmaceutical leadership experience, to serve as chairman of Celerity.  We are currently in discussions with other pharmaceutical companies interested in adopting this innovative new model of outsourcing to give them greater flexibility to support their drug development and realize the full value of their assets.

Dan Robins, Ph.D.


Work with us

Dan Robins, Ph.D., has 20 years of pharmaceutical industry experience focused principally on research and development.  He is the former vice president of global development for Mylan, where he was responsible for injectable products.  His former business, Bioniche Pharma, where he led research and development in Ireland, was acquired by Mylan in 2010.  Prior to Bioniche Pharma, Dan was vice president of product development for Abraxis BioScience (formerly American Pharmaceutical Partners Inc.)  He also held leadership positions at Barr Laboratories, Inc. and scientific roles at Schering-Plough Research Institute, Mallinckrodt Veterinary and Pentech Pharmaceuticals.  Dan received master’s and doctorate degrees in chemistry from The Ohio State University and his master’s degree in business administration from New York University. He earned his bachelor’s degree from LaSalle University.